<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365207</url>
  </required_header>
  <id_info>
    <org_study_id>14-002</org_study_id>
    <nct_id>NCT02365207</nct_id>
  </id_info>
  <brief_title>Intravesical BCG Administration to Patients With Invasive Bladder Cancer</brief_title>
  <official_title>Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment
      response) BCG intravesically followed by a cystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with muscle invasive (≥T1) bladder cancer will be given 3-6 treatments (based on
      treatment response) intravesical TICE® BCG. BCG is an attenuated, live culture preparation of
      the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis.

      After completion of BCG treatments the patient will undergo a cystectomy. A portion of
      bladder tumor tissue and lymph nodes will be collected for research purposes during the
      cystectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of BCG to enhance tumor specific immunity</measure>
    <time_frame>At cystectomy at 3-6 weeks after BCG treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Invasive bladder cancer treated with 3-6 weeks of intravesical BCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG strain of Mycobacterium bovis</intervention_name>
    <description>Invasive bladder cancer treated with 3-6 weeks of intravesical BCG</description>
    <arm_group_label>BCG</arm_group_label>
    <other_name>BCG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have suspected or known invasive (≥T1) bladder cancer

          2. Be able to give informed consent

          3. Be age 18 or older

          4. Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids &gt;1 month)

        Exclusion Criteria:

          1. Have non-invasive (&lt;T1) bladder cancer

          2. Unable to give informed consent

          3. &lt; 18 or older

          4. Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids &gt;1 month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Svatek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Svatek, MD</last_name>
    <phone>210-567-5676</phone>
    <email>svatek@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerri Kendrick, PA-C</last_name>
    <phone>210-567-5676</phone>
    <email>kendrick@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MARC - The University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Robert Svatek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

